Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (126)	11/18/2006 7:46:42 PM
From: dr.praveen	Respond to of 210

In the latest Nature biotech's paper on HSP90, nothing great though but it says researchers think HSP90 drugs work better in combo's rather than mono's. I feel you r comparing Infi 504 with Kosan DMAG very early. But for me none of them showed great results and I want to see some solid results either as a mono or a combo in many other tumours. DMAG was given at lower doses than was IPI-504, coz Cardiac toxicity was observed at the 32 mg/m2 dose, with one acute MI and one trop elevation, both in AML patients with significant comorbidities though.(Thats why I have been thinking Exelixis might reduce the dose on 999) Also In phase I NCI-sponsored trials of alvespimycin, reversible grade 3 and 4 shortness of breath was observed,but mostly in patients with preexisting pulmonary conditions and also they were using a more frequent dosing regimen than in Kosan’s trials. But since Infi's 504 didn't yet reach MTD, so they r planning to take take off the holiday period and give it continously. Dose limiting hepatotoxicity was seen in both trials of Kos 953 earlier.So you have to be watchful it doesn't show more in future with Velcade and show a positive risk benefit ratio.So far Kos953 seems to be doing well with Velcade and also fits into the dosage of twice per week regimen. But the diff in doses or the dose limiting toxicities of Infi and Kosan drugs don't matter much to me if they are found safe at the corresponding doses in future trials. Watch for Kosan's DMAG in combo with herceptin coz of long half life,colon and prostate ca too which will be interesting. After saying all of this, MLNM may scoop Kosan tom and you don't need to bother:-) Cheers, Praveen